RxDoctor Payments Data

Sharon Tucker, MD

Family Medicine · Mesquite, TXNPI 1548219975

Payments from drug & device makers

$576in general payments, 2019–2025

Across 33 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$129
  • GSK$91
  • Novo Nordisk$90
  • Lilly USA, LLC$43
  • Pfizer$41
  • Dexcom, Inc.$37
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$576 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$139,869
Medicare patients
316
Services billed
2,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$195,925
MounjaroTirzepatide72$96,890
JanuviaSitagliptin Phosphate42$47,334
EliquisApixaban44$46,812
JardianceEmpagliflozin26$35,336
TrulicityDulaglutide22$32,674
FarxigaDapagliflozin Propanediol15$23,338
XareltoRivaroxaban19$21,451
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$15,086
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,801
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$9,372
Humalog Kwikpen U-100Insulin Lispro11$7,726
SymbicortBudesonide/Formoterol Fumarate24$6,662
Dexlansoprazole DrDexlansoprazole11$4,394
Tresiba Flextouch U-100Insulin Degludec11$4,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$90$195,925150 claims
Lilly USA, LLCMounjaro, Trulicity$43$129,56494 claims
PfizerEliquis, Abrysvo$41$50,61057 claims
AstraZenecaFarxiga, Symbicort$14$30,00039 claims
AbbVieSynthroid$16$3,14745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →